Clinical Trial Update: Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of Alvespimycin hydrochloride in relapsed/refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, and small lymphocytic lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Alvespimycin hydrochloride (alvespimycin hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Status: TERMINATED